Newest GLP-1 medications. - Reddit

What do GLP-1 medications actually do?

GLP-1 stands for glucagon-like peptide-1, an incretin hormone produced in the gut in response to food intake. GLP-1 receptor agonists are synthetic analogues that mimic this hormone’s effects at pharmacological doses. Their primary mechanisms are slowing gastric emptying, reducing appetite through central nervous system signaling, and stimulating insulin secretion in a glucose-dependent manner.

The net clinical effect in non-diabetic adults is reduced caloric intake, gradual weight reduction, and in larger trials, evidence of cardiovascular risk reduction at high-dose semaglutide. These are weight management tools, not treatments for any disease in the compounded, non-diabetic context.

What is semaglutide, the first broadly accessible option?

Semaglutide is the active ingredient in Ozempic (diabetes indication) and Wegovy (weight management indication). It is a selective GLP-1 receptor agonist with a half-life long enough to support once-weekly dosing.

In the SURMOUNT and STEP trial programs, semaglutide at the approved 2.4 mg weekly dose produced average weight reductions of approximately 15% in non-diabetic adults with obesity over 68 weeks. The SELECT trial published in 2023 showed a 20% reduction in major adverse cardiovascular events in adults with overweight or obesity and established cardiovascular disease.

Compounded semaglutide, prepared by licensed 503A pharmacies in the United States, has been available through telehealth platforms while a documented shortage has remained in effect for branded semaglutide products. Compounded semaglutide contains semaglutide as its active ingredient but is not an FDA-approved finished formulation. No hidden overseas supply chain: PepScribe works exclusively with USA-based 503A pharmacies.

What makes tirzepatide a dual agonist?

Tirzepatide represents the next generation of incretin-based therapy. Rather than targeting only GLP-1 receptors, it is a dual GIP/GLP-1 receptor agonist — meaning it activates both the glucagon-like peptide-1 pathway and the glucose-dependent insulinotropic polypeptide (GIP) pathway simultaneously.

In the SURMOUNT-1 trial, tirzepatide at 15 mg weekly produced average weight reduction of approximately 22.5% in non-diabetic adults with obesity over 72 weeks — the largest average reduction reported in any phase III obesity pharmacotherapy trial at the time of publication. The SURMOUNT-5 head-to-head trial found greater average weight reduction with tirzepatide compared to semaglutide.

Compounded tirzepatide is available through licensed 503A pharmacies under the same shortage-based access framework as semaglutide. A clinician evaluates which compound is appropriate based on individual history, tolerability, and goals.

How do semaglutide, tirzepatide, and next-generation options compare?

What next-generation GLP-1 agonists are coming in trials?

Several next-generation compounds are in Phase III trials as of mid-2026. None are available through licensed compounding or FDA approval yet:

• Retatrutide: A triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. Phase II data showed average weight reduction exceeding 24% at the highest dose in non-diabetic adults. Phase III trials are ongoing.
• Orforglipron: An oral, non-peptide small-molecule GLP-1 receptor agonist from Eli Lilly. Because it is not a peptide, it can be taken in tablet form without degradation in the GI tract. Phase III data is expected in 2025 to 2026.
• CagriSema: A combination of cagrilintide (an amylin analogue) and semaglutide. Early data suggests additive weight reduction over semaglutide alone.

PepScribe does not offer compounds that are not accessible through licensed 503A pharmacies under current US regulations. The above are included as educational context for the evolving landscape, not as available options.

Compounded vs. branded: what the difference means for you

For patients who cannot access or afford branded GLP-1 medications, compounded versions from licensed 503A pharmacies have provided a meaningful pathway. The practical differences worth understanding:

• Regulatory status: Branded drugs are FDA-approved finished formulations. Compounded versions are not FDA-approved but are legal under the 503A compounding framework with a valid prescription.
• Inactive ingredients and devices: Compounded formulations may use different excipients, buffers, or delivery devices than branded products. Clinicians and pharmacists can advise on formulation details.
• Cost: Compounded versions are generally more affordable than branded products, particularly for patients without insurance coverage for weight management medication.
• Shortage dependency: Legal access to compounded semaglutide and tirzepatide is tied to official shortage status. This can change. Clinicians who work within a compliant framework monitor this and communicate changes to patients.

How do you access GLP-1 medications through a clinician?

All GLP-1 receptor agonists require a prescription. The access path through a telehealth platform like PepScribe works as follows:

• Complete a short intake that covers your weight management goals, relevant medical history, and any medications or supplements you are currently taking.
• A licensed clinician reviews your intake and determines clinical eligibility. Contraindications include a personal or family history of medullary thyroid carcinoma or MEN2 syndrome, active pancreatitis, and severe gastroparesis, among others.
• If appropriate, the clinician prescribes compounded semaglutide or tirzepatide through a licensed 503A pharmacy. The pharmacy ships directly to you.
• Follow-up check-ins allow dose adjustment based on tolerability and response. Most protocols start low and titrate over several weeks to minimize GI side effects.

Common questions answered